This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Patient Safety/ Medical Error  • Renal Diseases, Other  • Surgery  • Colorectal Surgery  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael Caswell, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

There were both factual errors and critical omissions in the articles by Khurana et al¹ and Roy and Bianchi² that are deserving of clarification. In their article, Khurana et al^1(pp593-594) stated " . . . the Food and Drug Administration (FDA) issued a Black Box warning recommending that OSPS [oral phosphosoda solution] . . . " without reference. Their statement is incorrect. The FDA has never issued a black box warning for Fleet Phospho-soda (C.B. Fleet Company Inc, Lynchburg, Virginia) or any other OSPS product. As cited in Roy and Bianchi,² the FDA issued a Science Background Paper and a MedWatch Alert in May 2006 on "Oral Sodium Phosphate (OSP) Products for Bowel Cleansing" (http://www.fda.gov/cder/drug/infopage/OSP_solution/default.htm), but no OSPS product is required to bear or bears a black box warning. For information on warnings and contraindications to use of the products and other safety-related information, see http://www.fleetlabs.com/healthcare_professionals_notices.php, as well as the Physician's Desk . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?